Leukemija klinikiniai tyrimai Ajova
7 tyrimai dėl Leukemija ieško dalyvių vietose Ajova.
Miestai Ajova
Oficialus tyrimo tekstas (anglų kalba)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Iowa, Iowa City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Iowa Hospitals & Clinics, Iowa City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788Integrated Cancer Repository for Cancer Research
- Methodist Jennie Edmundson Hospital, Council Bluffs
- Covenant Medical Center, Inc, Waterloo
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 19 iki 110 · Visoms lytims · Atnaujinta 2026-06-29 · NCT02012699A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Iowa Hospitals & Clinics, Iowa City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Activity Levels in Bone Marrow Transplant Patients
- University of Iowa, Iowa City
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2025-11-10 · NCT04115241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Iowa City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.